Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
We report the successful use of bortezomib to treat a patient with multiple myeloma (MM) who had extramedullary relapse (paraspinal and thoracic masses and multiple cranial nerve palsy) after autologous and non-myeloablative allogeneic hematopoietic stem cell transplantation (HSCT).
Patriarca
Francesca
F
Prosdocimo
Simonetta
S
Tomadini
Valentina
V
Vasciaveo
Annarosa
A
Bruno
Benedetto
B
Fanin
Renato
R
D000970:Antineoplastic Agents / Q000494:pharmacology; D001706:Biopsy; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy*; D011480:Protease Inhibitors / Q000494:pharmacology; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D014057:Tomography, X-Ray Computed; D014182:Transplantation, Autologous / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib